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Abstract
While depression is clearly associated with increased mortality after acute myocardial infarction,
there is a paucity of data examining the impact of depression on patients with unstable angina
(UA). We analyzed the relationship between depressive symptoms and all-cause mortality (ACM)
among patients with UA who were enrolled in a prospective multi-center study of depression and
acute coronary syndrome (ACS). Depressive symptoms were measured with the Beck Depression
Inventory (BDI) within 1 week of the ACS event, and patients were selected for BDI score 0 to 4,
or ≥10. Our sample included 209 UA patients, with 104 (50%) having BDI score ≥10.
Proportional hazards analyses adjusted for variables including left ventricular ejection fraction,
GRACE risk score, and Charlson comorbidity index. In multivariable analyses, BDI score ≥10
was associated with increased risk of 42-month ACM (HR=2.04, 95% CI 1.20–3.46, p=0.008)
compared with BDI score 0 to 4. In conclusion, our results confirm and extend prior evidence
linking depression to worse outcomes in UA, and suggest that interventions that address
depression may be worth examining across the spectrum of risk in ACS.
Keywords
depression; acute coronary syndrome
Introduction
Depression is associated with increased mortality risk after acute myocardial infarction
(MI), with an approximate relative risk of 2.4 for all-cause mortality (ACM) according to a
meta-analysis of 22 studies.1 However, there have been relatively few published studies of
depression as a predictor of mortality in unstable angina (UA).2 UA patients comprise about
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26 percent of hospitalized patients with acute coronary syndrome (ACS),3 and although
long-term prognosis is more favorable compared with MI patients,4 early invasive
revascularization strategies are less beneficial for prevention of recurrent events in UA
patients.5 In light of differences in pathophysiology and outcomes in UA compared with MI,
there may also be differences in the impact of risk factors such as depression on long-term
prognosis in UA patients. Given the relative paucity of data regarding the relationship
between depressive symptoms and mortality in UA patients, we sought to examine this
association in a prospective multi-center study of depression in ACS patients.
Methods
We performed an analysis of the Coronary Psychosocial Evaluation Studies (COPES), a
multi-site, observational cohort study designed to investigate the etiology and naturalistic
course of depressive symptoms after an ACS event.6,7 Participants were recruited from
among patients admitted to 3 university hospitals (Mount Sinai Hospital, New York, New
York, and Yale–New Haven Hospital and Hospital of St Raphael, New Haven, Connecticut)
for an ACS event between May 2003 and June 2005. The institutional review board of each
hospital approved the study. ACS events were defined according to AHA/ACC criteria8 as
either acute MI (with or without ST segment elevation) or UA. UA patients had symptoms
consistent with acute myocardial ischemia and at least one of the following: ischemic
electrocardiographic changes (i.e. ST depression and/or T-wave abnormalities), an
angiogram indicative of coronary artery disease on current admission, and/or documented
history of coronary artery disease. Patients with an acute rise in serum cardiac enzyme levels
were excluded. A study cardiologist confirmed ACS eligibility for all patients.
The Beck Depression Inventory (BDI),9 a self-report measure of depressive symptom
severity, was administered within one week after the index ACS event,10 and patients who
scored between 0 and 4 (indicative of no depressive symptoms) or ≥10 (at least mild
depressive symptoms) were included. Patients with BDI scores between 5 and 9 were
excluded to delineate more clearly depressed and non-depressed groups at baseline.11 For
this analysis, depressive symptoms were categorized into two groups according to BDI
score: ≥10, versus 0 to 4.
In addition to the assessment of depressive symptom severity with the BDI, a diagnosis of
major depression was also determined using the Diagnostic Interview with Structured
Hamilton (DISH), an interview format developed for the (Enhancing Recovery in Coronary
Heart Disease Patients (ENRICHD) clinical trial.12 Interviews were conducted by trained
research staff, and 1 clinical psychologist and 1 psychiatrist independently reviewed
audiotapes and written notes for each interview to verify all diagnoses.
Medical risk factors for long-term mortality were measured with the Global Registry of
Acute Coronary Events (GRACE) risk score13 and the Charlson comorbidity index.14 The
GRACE model includes advanced age, history of MI and heart failure, elevated pulse rate
and systolic blood pressure at presentation to the hospital, elevated initial serum creatinine
level, elevated initial cardiac enzyme level, ST-segment depression on electrocardiogram at
presentation, and percutaneous coronary intervention (PCI) performed in the hospital. The
GRACE risk score ranges from 1 to 263 points, with higher scores indicating higher
mortality risk. A score from 1 to 80 predicts a 1% mortality rate at 6 months; 100, a 2%
mortality rate; and higher than 210, a mortality rate greater than 50%.13 The Charlson index
includes 12 chronic conditions with weights according to their association with one-year
mortality, and has been associated with long-term survival in patients with coronary artery
disease.15
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Left ventricular ejection fraction (LVEF) was measured quantitatively by left
ventriculogram during cardiac catheterization (48% of patients), echocardiogram (38%), or
radionuclide study (12%). If multiple measures were available, the value from the
ventriculogram was used first, followed by the value from the echocardiogram. LVEF was
then classified as normal to mild dysfunction (LVEF ≥0.40) and moderate to severe
dysfunction (LVEF < 0.40). Data on LVEF were missing for 19 patients.
The primary end point was all-cause mortality (ACM). At 1, 3, 6, 18, 30, and 42 months
after enrollment, patients were contacted and follow-up assessments were completed either
by telephone or in person. For patients who could not be contacted or who were reported by
a relative to be deceased, the Social Security Death Index was searched to verify vital status.
Fisher exact chi-squared tests and 2-sample t-tests were used to compare categorical and
continuous measurements between the depressed (BDI ≥10) and non-depressed (BDI 0 to 4)
groups. Actuarial survival curves were plotted according to BDI score category. Cox
proportional hazards models were used to estimate the hazard ratio (HR) for ACM
associated with BDI score ≥10, stratified by hospital. Based on published findings of factors
that might confound the depression–ACM association, age, sex, LVEF, medical
comorbidities (Charlson index), and clinical prognostic index (GRACE) were included in
multivariable analyses. All analyses were performed using SPSS, version 16 (SPSS Inc,
Chicago, Illinois).
Results
Of the 457 enrolled ACS patients in COPES, 4 were excluded from the current analysis
because the psychiatric interview was not completed within the designated time. Of the
remaining 453 patients, 209 who met study criteria for UA were included in the analysis
(Table 1). Of this sample, 104 patients scored ≥10 on the BDI, indicating meaningful levels
of depressive symptoms. Compared to patients with minimal depressive symptoms (BDI<5),
those with meaningful symptoms were younger, more likely to be female, and had higher
Charlson comorbidity scores. Major depressive disorder by diagnostic interview was present
in 1 patient in the group with BDI<5 and in 29 patients in the group with BDI ≥10.
During an average follow-up of 30.5 + 11.5 months, 9 deaths occurred by 1 year and 23
deaths occurred by 42 months (Figure 1). In age- and sex-adjusted analyses, depression
(BDI score ≥10) was associated with 1-year ACM (HR 2.15, 95% CI 0.96–4.83, p=0.063)
and was significantly associated with 42-month ACM (HR 1.79, 95% CI 1.13–2.85,
p=0.014). In analyses that also included LVEF<0.40, Charlson score, and GRACE score,
there remained a trend toward increased 1-year mortality associated with BDI score ≥10,
and the relationship to 42-month ACM remained statistically significant without attenuation
(Table 2). Baseline major depressive disorder was not associated with 1-year or 42-month
ACM in multivariable analyses (HR=1.16 for 12-month ACM, HR=1.18 for 42-month
ACM, p>0.28 for both).
Discussion
In this prospective cohort study performed across 3 centers, UA patients with meaningful
depressive symptoms measured by BDI at the time of index hospitalization were at
increased risk for 42-month ACM, and the relative magnitude of risk was similar to that for
patients with acute MI. This relationship held despite multivariable adjustment for LVEF,
GRACE risk score, and Charlson comorbidity index. The great majority of research on
depression and post-ACS prognosis has focused on the population of patients admitted to
hospital with acute MI.1 Indeed, our results join those of only one prior study of which we
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aware, by Lesperance and colleagues,2 who in 2000 showed in a cohort of 430 UA patients
that those with elevated depressive symptoms were at higher risk for 1-year mortality. The
definitions for unstable angina and depressive symptoms used by both studies were similar.
Interestingly, depressive symptoms predict 1-year mortality in patients with MI, but not
mortality over a longer observation period.16 Our findings revealed that depressive
symptoms in UA patients conferred mortality risk at 42 months, but this relationship was not
statistically significant for 1-year mortality. Our results contribute to a broadening of our
understanding of the importance of depression, and are consistent with the concept that
depressive symptoms are associated with mortality in ACS cases across the spectrum of
cardiac risk.
The current findings are important to consider as research efforts to treat depression and to
offset cardiovascular risk are undertaken. ENRICHD, the largest randomized trial of
depression treatment for cardiac patients conducted to date, enrolled only patients meeting
criteria for acute MI and did not show a reduction in cardiovascular events associated with
the intervention.17 The recently completed COPES Phase I Randomized Trial18 enrolled
patients with both acute MI and UA. The results of this study demonstrated a trend to
reduced risk of major cardiovascular events and ACM associated with treatment for
persistent depressive symptoms in the months after the index ACS event. While the COPES
Trial was small and focused primarily on safety and patient satisfaction associated with a
collaborative care approach to depression treatment, the finding of reduced risk in the
intervention group raises important questions for future, larger scale treatment efforts.
Together with the recent trial data, the current analysis suggests that future large scale
depression interventions in cardiac populations should include patients with UA as well as
MI.
The prospective, multi-center study design and the systematic assessment of depressive
symptom severity represent important strengths of the current study. The few events and
relatively small cohort represent study limitations, although we were still able to detect a
relationship between depressive symptoms and ACM at 42 months in multivariable
analyses. In addition, we did not collect standardized measures of anxiety in our study, and
cannot compare the ACM risk between depression and anxiety. Furthermore, with few
patients demonstrating major depression, there was limited power to detect a significant
relationship between this level of depression severity and ACM risk. Nonetheless, our
results highlight the potential importance for post-ACS depression intervention trials that
target cardiovascular risk to include UA as well as acute MI.
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Actuarial survival according to Beck Depression Inventory (BDI) score category.
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Table 1
Baseline characteristics of unstable angina patients according to Beck Depression Inventory (BDI) category.
Variable BDI 0–4 (n=105) BDI ≥10 (n=104) P value
Age (years) (std. dev.) 63.7 (10.9) 58.5 (13.5) 0.003
Female 37 (35%) 60 (62%) 0.001
Non-white 23 (22%) 28 (27%) 0.42
LVEF<0.40 8 (8%) 12 (12%) 0.23
Mean GRACE score (std. dev.) 87.8 (27.5) 85.9 (32.8) 0.65
Mean Charlson score (std. dev.) 1.3 (1.5) 1.8 (1.6) 0.03
PCI during index admission 64 (54%) 54 (46%) 0.32
MDD at baseline 1 (3%) 29 (28%) 0.001
GRACE= Global Registry of Acute Coronary Events; LVEF=left ventricular ejection fraction; PCI=percutaneous coronary intervention;
MDD=major depressive disorder
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Table 2
Multivariable Cox regression for all-cause mortality among unstable angina patients (n=209).
1-year ACM (d=9) 42-month ACM (d=23)
Hazard Ratio (95% CI) P value Hazard Ratio (95% CI) P value
Age 1.02 (0.92–1.13) 0.74 1.04 (0.98–1.10) 0.21
Female 0.28 (0.09–0.91) 0.03 0.61 (0.37–1.02) 0.06
Charlson Score 1.52 (1.06–2.20) 0.02 1.62 (1.30–2.03) <0.01
Grace Score 1.03 (0.98–1.08) 0.29 1.01 (0.98–1.03) 0.72
LVEF <0.40 0.77 (0.09–6.53) 0.81 1.87 (0.62–5.63) 0.27
BDI score ≥10 1.91 (0.81–4.50) 0.14 2.04 (1.20–3.46) 0.008
d=deaths; ACM=all-cause mortality; CI=confidence interval; LVEF=left ventricular ejection fraction; BDI=Beck Depression Inventory
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